[Hypercalcemia in blood diseases and cancers]

Area of Science:

• Biochemistry
• Oncology
• Endocrinology

Context:

• The current clinical classification of malignant hypercalcemia based on bone lesions is outdated.
• Pathophysiology involves complex interactions of various substances, not solely bone involvement.

Purpose:

• To re-evaluate the classification of malignant hypercalcemia.
• To understand the role of specific mediators in hypercalcemia pathogenesis.
• To explore therapeutic targets for hypercalcemia.

Summary:

• Malignant hypercalcemia's classification based on bone lesions is inadequate.
• Focal osteolysis and humoral hypercalcemia involve multiple substances like prostaglandins, cytokines, growth factors, parathyroid hormone-related peptide (PTHrp), and calcitriol.
• PTHrp plays a significant role in humoral hypercalcemia affecting kidneys and bones.

Impact:

• Advances understanding of hypercalcemia pathophysiology.
• Suggests development of novel therapeutic antagonists.
• Highlights the need to study mediators in non-tumoral tissues.